Learn about the flu shot, COVID-19 vaccine, and our masking policy »
New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Get the iPhone MyHealth app »
Get the Android MyHealth app »
Abstract
Gastrointestinal bleeding due to arteriovenous malformations (AVM) is an increasingly recognized complication of continuous flow left ventricular assist devices (LVAD). Currently, therapeutic options for LVAD-associated AVMs are limited and often require repeated endoscopic procedures and reduction or cessation of anticoagulation. Thalidomide has been utilized in the treatment of refractory bleeding due to gastrointestinal vascular malformations. Here we describe the case of a 66-year-old patient with severe ischemic cardiomyopathy implanted with a continuous flow Heartmate II. His post-operative course was complicated by multiple hospital admissions for gastrointestinal bleeding due to LVAD-associated AVMs refractory to repeated argon plasma laser coagulation (APC). Anticoagulation was discontinued with subsequent pump stoppage due to thrombus requiring urgent surgical pump exchange. Following this, thalidomide was initiated and anticoagulation with warfarin was continued. Since initiation of thalidomide, the patient has not had further gastrointestinal bleeding or evidence of pump thrombus in the subsequent 1 year.
View details for DOI 10.1097/MAT.0000000000000087
View details for PubMedID 24830804